Brief: Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio
14/04/2025 14:26
April 14 (Reuters) - Coherus BioSciences Inc CHRS.O: ACCORD BIOPHARMA, INC. ANNOUNCES COMPLETION OF UDENYCA® (PEGFILGRASTIM-CBQV) FRANCHISE ACQUISITION FROM COHERUS BIOSCIENCES, INC., EXPANDING U.S. BIOSIMILAR PORTFOLIO Source text: ID:nPn7031Dwa Further company coverage: CHRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coherus Oncology
See all newsBrief: Coherus Oncology Initiates Process To Sell Legacy Biosim Assets
Brief: Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights
Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Brief: Coherus Oncology Q2 Net Income USD -20.631 Million